Exact Sciences (EXAS) Tops Q2 EPS by 11c

Exact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.94), $0.11 better than the analyst estimate of ($1.05). Revenue for the quarter came in at $522 million versus the consensus estimate of $497.18 million.

GUIDANCE:

Exact Sciences sees Q3 2022 revenue of $1.98-2.022 billion, versus the consensus of $2.02 billion.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• After-Hours Stock Movers: FDX, CBRS, NKE
• CVG to join Russell 2000 and Russell 3000 indexes June 26